Chiodera P, Volpi R, Delsignore R, Marchesi C, Salati G, Camellini L, Rossi G, Coiro V
Br J Clin Pharmacol. 1986 Oct;22(4):479-82. doi: 10.1111/j.1365-2125.1986.tb02921.x.
This study was performed in order to investigate the dopaminergic mechanism involved in the control of arginine-vasopressin (AVP) secretion in normal men. Plasma AVP concentrations were measured before and after the administration of an i.v. bolus of 10 mg metoclopramide or domperidone to twelve healthy males. Metoclopramide, a cerebral and peripheral antagonist of dopaminergic receptors, significantly stimulated AVP secretion, whereas domperidone, a dopamine antagonist which does not cross the blood-brain barrier, was without effect. These data suggest that metoclopramide stimulates the release of AVP by blocking dopaminergic receptors in structures located inside the blood-brain barrier. Alternatively, it is possible that the stimulation of AVP release induced by metoclopramide does not occur through inhibition of dopamine receptors but rather through interaction with other neuroendocrine pathways.
进行这项研究是为了探究正常男性中参与精氨酸加压素（AVP）分泌调控的多巴胺能机制。对12名健康男性静脉推注10毫克胃复安或多潘立酮前后，测量其血浆AVP浓度。胃复安是一种多巴胺能受体的中枢和外周拮抗剂，可显著刺激AVP分泌，而多潘立酮是一种不能穿过血脑屏障的多巴胺拮抗剂，无此作用。这些数据表明，胃复安通过阻断血脑屏障内结构中的多巴胺能受体来刺激AVP释放。或者，胃复安诱导的AVP释放刺激可能不是通过抑制多巴胺受体发生的，而是通过与其他神经内分泌途径相互作用实现的。
